Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


1.		Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				16 to 75				Other				CGC05MK1002 NCT00188149

Last Modified: 1/6/2009 First Published: 11/1/2002


2.		Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 60				Other				EORTC-20012 GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595

Last Modified: 1/23/2007 First Published: 11/24/2002


3.		Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				MRC-BR12 EU-20114, ISRCTN83176944, NCT00052455

First Published: 2/5/2007


4.		Phase III Randomized Study of Early Fludeoxglucose F 18 Positron Emission Tomography Scan-Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Previously Untreated Supradiaphragmatic Stage I or II Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				15 to 70				Other				EORTC-20051 GELA-H10, EUDRACT-2005-002765-37, NCT00433433

Last Modified: 6/19/2008 First Published: 2/5/2007


5.		Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic, Treatment				Active				Under 18				Other				EURONET-PHL-C1 EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10


6.		HD18 for Advanced Stages in Hodgkins Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				HD18 NCT00515554

Last Modified: 9/30/2008 First Published: 5/8/2008


7.		Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CRUK-2007-006064-30 2007-006064-30, CRUK-07/146, NCT00678327

Last Modified: 1/8/2009 First Published: 2/20/2004


8.		Phase II Study of Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Older Patients With Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 60				Other				UON-SHIELD EU-20346, NCT00079105


9.		Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				0904-473 NCT00151281

Last Modified: 12/20/2008 First Published: 5/23/2006


10.		Phase II Study of Rituximab in Combination With Standard Chemotherapy Comprising Methotrexate, Vincristine, Procarbazine Hydrochloride, and Cytarabine in Patients With Primary Central Nervous System Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E1F05 E1F05, NCT00335140

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute